Description: MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate includes AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company also develops MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
Home Page: www.mannkindcorp.com
MNKD Technical Analysis
30930 Russell Ranch Road
Westlake Village,
CA
91362
United States
Phone:
818 661 5000
Officers
| Name | Title |
|---|---|
| Dr. Michael E. Castagna Pharm.D. | CEO & Director |
| Mr. Steven B. Binder | Chief Financial Officer |
| Mr. Joseph Kocinsky M.B.A., M.S. | Chief Technology Officer |
| Dr. David B. Thomson | Exec. VP, Gen. Counsel & Sec. |
| Dr. Stuart A. Tross Ph.D. | Chief People & Workplace Officer |
| Mr. Thomas Hofmann M.D., Ph.D. | Chief Scientific Officer |
| Ms. Rosabel Realica Alinaya | VP of Investor Relations & Treasury |
| Mr. John F. Bedard | Sr. VP of Worldwide Regulatory Affairs |
| Mr. James Patrick McCauley Jr., J.D., M.B.A. | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 303.0303 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 16.5046 |
| IPO Date: | 2004-07-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 348 |